Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply: Strengths and Limitations of the Renal Locoregional Perfusion Platform.

JACC. Basic to translational science·2026
Same author

Edoxaban for atrial fibrillation in patients with atherosclerotic disease in daily clinical practice.

Journal of thrombosis and thrombolysis·2026
Same author

Incidence and Predictors of Successful Lead Extraction With Short Active Mechanical Extraction Sheaths Only.

Journal of cardiovascular electrophysiology·2026
Same author

Surgical and procedural bleed risk stratification for anticoagulated patients undergoing planned surgery: guidance from the ISTH SSC Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Next-Generation Percutaneous Catheter-Based Closed-Loop Perfusion Concept Enables High-Precision Organ Delivery of Advanced Therapies.

JACC. Basic to translational science·2025
Same author

Impact of weight/BMI on clinical and bleeding events in 26 805 atrial fibrillation patients on edoxaban from the Global ETNA-AF Registry.

European journal of preventive cardiology·2025
Same journal

Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures.

Postgraduate medicine·2026
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
Same journal

Operational and demographic predictors of leaving without being seen in a high-volume tertiary emergency department: a five-year case-control study.

Postgraduate medicine·2026
Same journal

Risk of adverse effects of the concomitant use of statins with calcium channel blockers: a systematic review and meta-analysis.

Postgraduate medicine·2026
Same journal

Association between frailty and major chronic disease-free life expectancy: a large community-based longitudinal study.

Postgraduate medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Recent advances in cardiac resynchronization therapy.

Jan Steffel1, Johannes Holzmeister, William T Abraham

  • 1Cardiac Arrythmia Unit, Department of Cardiology, University Hospital, Zurich, Zurich, Switzerland. steffel@access.uzh.ch

Postgraduate Medicine
|April 9, 2011
PubMed
Summary
This summary is machine-generated.

Cardiac resynchronization therapy (CRT) improves outcomes for heart failure patients. Recent trials support CRT use in mildly symptomatic patients, expanding European guidelines.

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts
08:43

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts

Published on: August 26, 2021

Related Experiment Videos

Last Updated: Jun 3, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts
08:43

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts

Published on: August 26, 2021

Area of Science:

  • Cardiology
  • Heart Failure Management
  • Cardiac Electrophysiology

Background:

  • Cardiac resynchronization therapy (CRT) is standard for severe heart failure (NYHA class III-IV) with reduced ejection fraction and wide QRS.
  • Emerging evidence suggests CRT benefits mildly symptomatic patients (NYHA class II).

Purpose of the Study:

  • To review landmark trials (REVERSE, MADIT-CRT, RAFT) evaluating CRT efficacy.
  • To discuss expanding indications for CRT in heart failure management.

Main Methods:

  • Critical evaluation of randomized controlled trials.
  • Analysis of data on CRT in diverse patient subgroups.

Main Results:

  • Landmark trials confirm CRT's benefit in severe heart failure.
  • CRT shows promise for mildly symptomatic patients (NYHA class II), leading to guideline updates.
  • Evidence is growing for CRT in patients with mildly reduced ejection fraction or narrow QRS.

Conclusions:

  • CRT is a cornerstone therapy for heart failure with specific criteria.
  • Expanded indications for CRT are supported by recent evidence and evolving guidelines.
  • Further research may clarify CRT's role in broader patient populations.